

Q3 20-21 Performance in Delivering

Study Protocol Id	Research Ethics Committee Reference Number	Integrated Research Application System Number	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial	Comments
50467	18/LO/0381	240085	A Phase II/III Randomised, Double-blind, Placebo-controlled, Multicentre Study to Evaluate the Safety and Efficacy of BI 655130 Induction Therapy in patients with moderate-to-severely active ulcerative colitis who have failed previous biologics ther	Number Agreed	2	2	Date Agreed	31/05/2020	2	04/02/2020	2	Recruitment Finished	
50468	19/LO/0397	243173	A Phase 2/3, Randomized, Double-blind, Placebo-and Active-controlled, Parallel-group, Multicenter Protocol to Evaluate the Efficacy and Safety of Guselkumab in Participants with Moderately to Severely Active Crohn's Disease	Number Agreed	1	1	Date Agreed	01/05/2021	0	06/02/2020	0	Withdrawn By Host	Bamsley have withdrawn from the study at this time due to concerns regarding the IMP preparation
50469	17/NE/0351	235420	A PERFORMANCE EVALUATION STUDY OF ARQUER'S MCM5 ELISA TEST TO AID IN THE DIAGNOSIS OF PROSTATE CANCER	Number Agreed	13	13	Date Agreed	31/03/2020	13	31/03/2020	13	Recruitment Finished	
50470	17/EE/0401	224915	A Multicenter, Randomized, Double-Blind, Placebo-Controlled Induction Study to Assess the Efficacy and Safety of Risankizumab in Subjects with Moderately to Severely Active Crohn's Disease Who Failed Prior Biologic Treatment	Number Agreed	3	3	Date Agreed	29/07/2020	0	24/07/2020	0	Recruitment Finished	early finish - closed by sponsor
50471	17/EE/0402	224923	A Multicenter, Randomized, Double-Blind, Placebo Controlled 52-Week Maintenance and an Open-Label Extension Study of the Efficacy and Safety of Risankizumab in Subjects with Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991	Number Agreed	0	0	Date Agreed	30/09/2020	0	24/07/2020	0	Recruitment Finished	feeder study closed with) patients, no patients to roll over therefore closed
50472	18/LO/1387	246858	An open label, long term safety trial of BI 655130 treatment in patients with moderate to severely active ulcerative colitis who have completed previous BI 655130 trials.	Number Agreed	0	0	Date Agreed	25/12/2022	0	06/10/2020	0	Withdrawn By Sponsor	Study was withdrawn by Sponsor at site as the original study has had early termination and we had no patients who were due to roll onto this open label trial
50473	19/YH/0400	271539	A Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal, Parallel Group Study of Patiromer for the Management of Hyperkalemia in Subjects Receiving Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Medications for the Treatment of	Number Agreed	3	3	Date Agreed	31/03/2021	0	27/11/2020	0	Withdrawn By Host	No eligibile patients - Due to COVID we have seen a decrease in admission of these patients.